RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
View Patent ↗RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
1. A composition comprising an interfering RNA and a pharmaceutically acceptable carrier wherein said interfering RNA comprises a double stranded RNA having a first strand 19-49 nucleotides in length and a second strand 19-49 nucleotides in length wherein the first strand comprises SEQ ID NO: 79 or SEQ ID NO: 80.
2. The composition of claim 1 , wherein the first strand and the second strand are each 19-27 nucleotides in length.
3. The composition of claim 2 , wherein the first strand and the second strand are each 19-25 nucleotides in length.
4. The composition of claim 3 , wherein the first strand and the second strand are each 19-23 nucleotides in length.
5. The composition of claim 1 , wherein the interfering RNA molecule has blunt ends.
6. The composition of claim 1 , wherein at least one strand of the interfering RNA molecule comprises a 3′ overhang.
7. The composition of claim 6 , wherein the 3′ overhang comprises about 1 to about 6 nucleotides.
8. The composition of claim 7 , wherein the 3′ overhang comprises 2 nucleotides.
9. The composition of claim 1 , wherein the interfering RNA molecule comprises at least one modified nucleotide.
10. The composition of claim 9 wherein the modified nucleotide is a 2′-modified nucleotide.
11. The composition of claim 10 wherein the 2′-modified nucleotide is selected from the group consisting of: 2′-deoxy nucleotide, 2′-amino nucleotide, 2′-O-methyl nucleotide, 2′-methoxyethyl nucleotide.
12. The composition of claim 1 wherein the sense strand or the antisense strand contains a phosphorothioate linkage.
13. The composition of claim 1 , wherein the interfering RNA molecule is a siRNA.